Xeris Biopharma Holdings, Inc. (XERS) Stock Forecast
XERS analyst forecast
as of October 17, 2026- Analyst consensus
- Strong buy 4.57 / 5 from 7 analysts
- Price target
- $12.86 average of analyst targets
- Upside to target
- +24.7% from the latest close
- Next earnings
- November 5, 2026 EPS estimate $0.02
- 52-week range
- $5.29 – $10.48
XERS analyst ratings
7 analystsNumber of analysts at each rating.
XERS price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
XERS earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.03 | −$0.15 | $0.04 | $0.00 | 0.0% | 3 |
| Current fiscal year (2026) | −$0.02 | −$0.10 | $0.08 | $0.00 | 0.0% | 3 |
| Next fiscal year (2027) | $0.37 | $0.23 | $0.63 | −$0.02 | +2,319.6% | 3 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
XERS revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $101.7M | $100.0M | $103.0M | +36.7% | 6 |
| Current fiscal year (2026) | $387.9M | $385.7M | $390.9M | +32.9% | 6 |
| Next fiscal year (2027) | $480.0M | $458.5M | $510.1M | +23.8% | 6 |
XERS EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
XERS revenue: reported and forecast
XERS EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0.04 | $0.04 | −$0.02 | −$0.02 | −$0.03 | −162.8% | 0 up · 1 down |
| Current fiscal year (2026) | $0.14 | $0.07 | −$0.00 | −$0.00 | −$0.02 | −111.7% | 0 up · 1 down |
| Next fiscal year (2027) | $0.40 | $0.38 | $0.39 | $0.39 | $0.37 | −6.3% | 0 up · 1 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
XERS earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; XERS beat in 6 of 12.
What analysts expect from XERS
7 analysts cover Xeris Biopharma; their consensus rating is strong buy (4.57 on a 1–5 scale, where 5 is a strong buy). The average price target is $12.86, 24.7% above the latest close of $10.31. Analysts expect earnings of −$0.02 per share for 2026, 0.0% from a year earlier. For 2027 the average estimate is $0.37 per share on revenue of $480.0 million. Xeris Biopharma beat the EPS estimate in 6 of the last 12 quarters.
Related: XERS income statement, XERS key metrics, XERS chart. See the XERS stock overview for the latest quote and news.
XERS forecast FAQ
What is Xeris Biopharma's price target?
The average analyst price target for Xeris Biopharma is $12.86, 24.7% above the latest close of $10.31.
Is Xeris Biopharma a buy, hold or sell?
Of 7 analysts covering Xeris Biopharma, 5 rate it a strong buy, 1 a buy, 1 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Xeris Biopharma's EPS forecast?
Analysts forecast −$0.02 per share for 2026 (range −$0.10 to $0.08); for 2027 the estimate is $0.37.
What is Xeris Biopharma's revenue forecast?
The average revenue estimate for 2026 is $387.9 million, growth of 32.9%; for 2027 it is $480.0 million.
When does Xeris Biopharma report earnings?
Xeris Biopharma is expected to report results for the quarter ending September 30, 2026 on November 5, 2026 before the market opens; the EPS estimate is $0.02.
Does Xeris Biopharma usually beat earnings estimates?
Xeris Biopharma reported EPS at or above the analyst estimate in 6 of the last 12 quarters.